||||||||||elsunersen (PRAX-222) / RogCon, Praxis Precision Medicines Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_1030; Together with EMBRAVE Part 1 findings, clinical experience in ongoing emergency use programs in the US, Germany, and Australia demonstrate a well-tolerated, consistent and meaningful therapeutic response to elsunersen. Ongoing follow up will determine long-term effect on seizures and associated comorbidities.
||||||||||elsunersen (PRAX-222) / RogCon, Praxis Precision Medicines Enrollment open, Trial completion date: A Clinical Trial of PRAX-222 in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy (clinicaltrials.gov) - Oct 4, 2024 P1/2, N=60, Recruiting, Sponsor: Praxis Precision Medicines Ongoing follow up will determine long-term effect on seizures and associated comorbidities. Active, not recruiting --> Recruiting | Trial completion date: Feb 2026 --> Sep 2027
||||||||||RC 222 / RogCon Journal: Trait-based mapping to identify the genetic factors underlying anaerobic germination of rice: Phenotyping, GXE, and QTL mapping. (Pubmed Central) - Oct 4, 2020 The QTLs identified through this study will allow the improvement of breeding lines for the trait through marker-assisted selection or through forward breeding approaches such as genomic selection. The high frequency of the BJ1 allele of these QTLs will enhance the robustness of germination under anaerobic conditions in inbred and hybrid rice varieties.